{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T23:22:19Z","timestamp":1773098539554,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Medical Health Science and Technology Project of Zhejiang Province","award":["2024KY364"],"award-info":[{"award-number":["2024KY364"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-00987-z","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T17:25:04Z","timestamp":1754933104000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The inhibitory effect of tyrosine kinase inhibitors on angiogenesis in zebrafish and interrelationship with the activation of the PI3K\/AKT pathway"],"prefix":"10.1186","volume":"26","author":[{"given":"Lili","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaotian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"issue":"2","key":"987_CR1","first-page":"455","volume":"59","author":"CS Melincovici","year":"2018","unstructured":"Melincovici CS, Bo\u015fca AB, \u015eu\u015fman S, et al. Vascular endothelial growth factor (VEGF)-key factor in normal and pathological angiogenesis. Rom J Morphol Embryol. 2018;59(2):455\u201367.","journal-title":"Rom J Morphol Embryol"},{"key":"987_CR2","doi-asserted-by":"publisher","first-page":"124018","DOI":"10.1016\/j.ijpharm.2024.124018","volume":"655","author":"P Jansook","year":"2024","unstructured":"Jansook P, Loftsson T, Stef\u00e1nsson E. Drug-like properties of tyrosine kinase inhibitors in ophthalmology: formulation and topical availability. Int J Pharm. 2024;655:124018. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.124018.","journal-title":"Int J Pharm"},{"issue":"2","key":"987_CR3","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/joim.12019","volume":"273","author":"WL Claesson","year":"2013","unstructured":"Claesson WL, Welsh M. VEGFA and tumour angiogenesis. J Intern Med. 2013;273(2):114\u201327. https:\/\/doi.org\/10.1111\/joim.12019.","journal-title":"J Intern Med"},{"issue":"7","key":"987_CR4","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1038\/s41401-021-00803-4","volume":"43","author":"HJ Wang","year":"2022","unstructured":"Wang HJ, Ran HF, Yin Y, et al. Catalpol improves impaired neurovascular unit in ischemic stroke rats via enhancing VEGF-PI3K\/AKT and VEGF-MEK1\/2\/ERK1\/2 signaling. Acta Pharmacol Sin. 2022;43(7):1670\u201385. https:\/\/doi.org\/10.1038\/s41401-021-00803-4.","journal-title":"Acta Pharmacol Sin"},{"key":"987_CR5","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ygyno.2023.05.007","volume":"174","author":"BJ Rimel","year":"2023","unstructured":"Rimel BJ, Crane EK, Hou J, et al. Tyrosine kinase inhibitor toxicities: A society of gynecologic oncology review and recommendations. Gynecol Oncol. 2023;174:148\u201356. https:\/\/doi.org\/10.1016\/j.ygyno.2023.05.007.","journal-title":"Gynecol Oncol"},{"issue":"16","key":"987_CR6","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1158\/1078-0432.CCR-22-3901","volume":"29","author":"SM Lim","year":"2023","unstructured":"Lim SM, Fujino T, Kim C, et al. BBT-176, a novel fourth-generation tyrosine kinase inhibitor for osimertinib-resistant EGFR mutations in non\u2013small cell lung cancer. Clin Cancer Res. 2023;29(16):3004\u201316. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3901.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"987_CR7","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.bcp.2012.09.023","volume":"84","author":"BB Hasinoff","year":"2012","unstructured":"Hasinoff BB, Wu X, Nitiss JL, et al. The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II. Biochem Pharmacol. 2012;84(12):1617\u201326. https:\/\/doi.org\/10.1016\/j.bcp.2012.09.023.","journal-title":"Biochem Pharmacol"},{"key":"987_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1476-4598-13-21","volume":"13","author":"S Gaur","year":"2014","unstructured":"Gaur S, Chen L, Ann V, et al. Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status. Mol Cancer. 2014;13:21. https:\/\/doi.org\/10.1186\/1476-4598-13-21.","journal-title":"Mol Cancer"},{"issue":"3","key":"987_CR9","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jhep.2011.09.017","volume":"56","author":"H Huynh","year":"2012","unstructured":"Huynh H, Chow PK, Tai WM, et al. Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma. J Hepatol. 2012;56(3):595\u2013601. https:\/\/doi.org\/10.1016\/j.jhep.2011.09.017.","journal-title":"J Hepatol"},{"issue":"9","key":"987_CR10","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1097\/ICO.0000000000002012","volume":"38","author":"B Sahan","year":"2019","unstructured":"Sahan B, Ciftci F, Eyuboglu S, et al. Comparison of the effects of dovitinib and bevacizumab on reducing neovascularization in an experimental rat corneal neovascularization model. Cornea. 2019;38(9):1161\u20138. https:\/\/doi.org\/10.1097\/ICO.0000000000002012.","journal-title":"Cornea"},{"issue":"3","key":"987_CR11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1134\/S000629792403009X","volume":"89","author":"N Shaban","year":"2024","unstructured":"Shaban N, Raevskiy M, Zakharova G, et al. Human blood serum counteracts EGFR\/HER2-Targeted drug lapatinib impact on squamous carcinoma SK-BR-3 cell growth and gene expression. Biochem (Mosc). 2024;89(3):487\u2013506. https:\/\/doi.org\/10.1134\/S000629792403009X.","journal-title":"Biochem (Mosc)"},{"issue":"5","key":"987_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/ceo.12500","volume":"43","author":"MK Kaya","year":"2015","unstructured":"Kaya MK, Demir T, Bulut H, et al. Effects of lapatinib and trastuzumab on vascular endothelial growth factor in experimental corneal neovascularization. Clin Exp Ophthalmol. 2015;43(5):449\u201357. https:\/\/doi.org\/10.1111\/ceo.12500.","journal-title":"Clin Exp Ophthalmol"},{"issue":"5","key":"987_CR13","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s10840-022-01400-z","volume":"66","author":"M Fazal","year":"2023","unstructured":"Fazal M, Wei C, Chuy KL, et al. Tyrosine kinase inhibitor-associated ventricular arrhythmias: a case series and review of literature. J Interv Card Electrophysiol. 2023;66(5):1165\u201375. https:\/\/doi.org\/10.1007\/s10840-022-01400-z","journal-title":"J Interv Card Electrophysiol"},{"key":"987_CR14","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.gene.2019.02.076","volume":"698","author":"S Noorolyai","year":"2019","unstructured":"Noorolyai S, Shajari N, Baghbani E, et al. The relation between PI3K\/AKT signalling pathway and cancer. Gene. 2019;698:120\u20138. https:\/\/doi.org\/10.1016\/j.gene.2019.02.076.","journal-title":"Gene"},{"issue":"1","key":"987_CR15","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22(1):138. https:\/\/doi.org\/10.1186\/s12943-023-01827-6.","journal-title":"Mol Cancer"},{"issue":"3","key":"987_CR16","doi-asserted-by":"publisher","first-page":"G387","DOI":"10.1152\/ajpgi.00350.2018","volume":"316","author":"ZT Jing","year":"2019","unstructured":"Jing ZT, Liu W, Xue CR, et al. AKT activator SC79 protects hepatocytes from TNF-\u03b1-mediated apoptosis and alleviates d-Gal\/LPS-induced liver injury. Am J Physiol Gastrointest Liver Physiol. 2019;316(3):G387\u201396. https:\/\/doi.org\/10.1152\/ajpgi.00350.2018.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"987_CR17","doi-asserted-by":"publisher","first-page":"5391","DOI":"10.12659\/MSM.910191","volume":"24","author":"Q Luan","year":"2018","unstructured":"Luan Q, Pan L, He D, et al. SC79, the AKT activator protects cerebral ischemia in a rat model of ischemia\/Reperfusion injury. Med Sci Monit. 2018;24:5391\u20137. https:\/\/doi.org\/10.12659\/MSM.910191.","journal-title":"Med Sci Monit"},{"issue":"1\u20132","key":"987_CR18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11010-019-03592-x","volume":"461","author":"JL Zhu","year":"2019","unstructured":"Zhu JL, Wu YY, Wu D, et al. SC79, a novel Akt activator, protects dopaminergic neuronal cells from MPP\u2009+\u2009and rotenone. Mol Cell Biochem. 2019;461(1\u20132):81\u20139. https:\/\/doi.org\/10.1007\/s11010-019-03592-x.","journal-title":"Mol Cell Biochem"},{"issue":"9","key":"987_CR19","doi-asserted-by":"publisher","first-page":"113028","DOI":"10.1016\/j.celrep.2023.113028","volume":"42","author":"P Cai","year":"2023","unstructured":"Cai P, Ni R, Lv M, et al. VEGF signaling governs the initiation of biliary-mediated liver regeneration through the PI3K-mTORC1 axis. Cell Rep. 2023;42(9):113028. https:\/\/doi.org\/10.1016\/j.celrep.2023.113028.","journal-title":"Cell Rep"},{"issue":"7","key":"987_CR20","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/bjp.2008.249","volume":"154","author":"TP Barros","year":"2008","unstructured":"Barros TP, Alderton WK, Reynolds HM, et al. Zebrafish: an emerging technology for in vivo Pharmacological assessment to identify potential safety liabilities in early drug discovery. Br J Pharmacol. 2008;154(7):1400\u201313. https:\/\/doi.org\/10.1038\/bjp.2008.249.","journal-title":"Br J Pharmacol"},{"key":"987_CR21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/B978-0-12-386930-2.00005-7","volume":"124","author":"RN Wilkinson","year":"2014","unstructured":"Wilkinson RN, van Eeden FJ. The zebrafish as a model of vascular development and disease. Prog Mol Biol Transl Sci. 2014;124:93\u2013122. https:\/\/doi.org\/10.1016\/B978-0-12-386930-2.00005-7.","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"9","key":"987_CR22","doi-asserted-by":"publisher","first-page":"4856","DOI":"10.3390\/ijms22094856","volume":"22","author":"RM Basnet","year":"2021","unstructured":"Basnet RM, Zizioli D, Musc\u00f2 A, et al. Caffeine inhibits direct and indirect angiogenesis in zebrafish embryos. Int J Mol Sci. 2021;22(9):4856. https:\/\/doi.org\/10.3390\/ijms22094856.","journal-title":"Int J Mol Sci"},{"key":"987_CR23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.freeradbiomed.2023.12.021","volume":"212","author":"K Xu","year":"2024","unstructured":"Xu K, Fei W, Gao W, et al. SOD3 regulates FLT1 to affect bone metabolism by promoting osteogenesis and inhibiting adipogenesis through PI3K\/AKT and MAPK pathways. Free Radic Biol Med. 2024;212:65\u201379. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2023.12.021","journal-title":"Free Radic Biol Med"},{"issue":"3","key":"987_CR24","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1186\/s12943-018-0793-1","volume":"24","author":"LY Tian","year":"2023","unstructured":"Liu Q, Yu S, Zhao W, et al. EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol Cancer. 2018;17(1):53. https:\/\/doi.org\/10.1186\/s12943-018-0793-1.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"987_CR25","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.cllc.2024.02.005","volume":"25","author":"B Khokhar","year":"2024","unstructured":"Tian LY, Smit DJ, J\u00fccker M. The Role of PI3K\/AKT\/mTOR Signaling in Hepatocellular Carcinoma Metabolism. Int J Mol Sci. 2023;24(3):2652. https:\/\/doi.org\/10.3390\/ijms24032652.","journal-title":"Clin Lung Cancer"},{"key":"987_CR26","doi-asserted-by":"publisher","first-page":"105979","DOI":"10.1016\/j.jsbmb.2021.105979","volume":"214","author":"J Garc\u00eda-Quiroz","year":"2021","unstructured":"Khokhar B, Chiang B, Iglay K, et al. QT-Interval prolongation, torsades de pointes, and heart failure with egfr tyrosine kinase inhibitors in non-small cell lung cancer: systematic review. Clin Lung Cancer. 2024;25(4):285\u2013318. https:\/\/doi.org\/10.1016\/j.cllc.2024.02.005.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"987_CR27","doi-asserted-by":"publisher","unstructured":"Fazal M, Wei C, Chuy KL, et al. Tyrosine kinase inhibitor-associated ventricular arrhythmias: a case series and review of literature. J Interv Card Electrophysiol. 2023;66(5):1165\u201375. https:\/\/doi.org\/10.1007\/s10840-022-01400-z.","DOI":"10.1007\/s10840-022-01400-z"},{"key":"987_CR28","doi-asserted-by":"publisher","unstructured":"Garc\u00eda-Quiroz J, C\u00e1rdenas-Ochoa N, Garc\u00eda-Becerra R, et al. Antitumoral effects of dovitinib in triple-negative breast cancer are synergized by calcitriol in vivo and in vitro. J Steroid Biochem Mol Biol. 2021;214:105979. https:\/\/doi.org\/10.1016\/j.jsbmb.2021.105979.","DOI":"10.1016\/j.jsbmb.2021.105979"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00987-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-00987-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00987-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T17:25:05Z","timestamp":1754933105000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-00987-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["987"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-00987-z","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"assertion":[{"value":"28 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Transgenic Fli-1:EGFP and wild-type AB zebrafish were bred and provided by the Hangzhou Hunter Biotech limited liability company. The use of experimental animals was permitted under license number: SYXK (Zhe) 2022-0004. Husbandry management met the requirements of the international AAALAC accreditation (Certification No.: 001458). Ethical review by the Institutional Animal Care and Use Committee (IACUC) was approved under protocol number: IACUC-2023-6895-01.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"148"}}